RBC Capital Reiterates Buy Rating for Viridian Therapeutics
RBC Capital has maintained its buy rating for Viridian Therapeutics with a $35 price target, a 90.53% upside from the current price.
Key Points
- RBC Capital reiterated its buy rating for Viridian Therapeutics with a $35 price target on June 30, 2026.
- RBC Capital's $35 price target implies 90.53% upside from Viridian Therapeutics, Inc.'s ($VRDN) current $18.37 share price.
- Viridian Therapeutics has a market cap of $2.03 billion and a 52-week range between $13.18 and $34.29.
- FMR LLC and BlackRock increased their stakes, with BlackRock adding 1,399,552 shares, now holding 7,831,475 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 30, 2026, RBC Capital reiterated its buy rating for Viridian Therapeutics, Inc. (NasdaqCM: VRDN), maintaining a price target of $35. Shares of Viridian traded at $18.79 on Wednesday.
RBC Capital vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Viridian Therapeutics
Several institutional investors have adjusted their positions in Viridian Therapeutics. FMR LLC grew its holdings by 994,921 shares, ending with 15,379,377 shares valued at approximately $300.8 million. BlackRock, Inc. increased its stake by 1,399,552 shares, reaching a total of 7,831,475 shares worth about $153.2 million. Bellevue Group AG made a significant addition of 2,367,617 shares, now holding 6,726,144 shares valued at $131.6 million. State Street Corp also boosted its position by 1,206,325 shares to 4,672,885 shares, with a value of $91.4 million. Vanguard Capital Management LLC opened a new position with 4,167,201 shares valued at $81.5 million.
Viridian Therapeutics, Inc. Stock Down 20.4%
Shares of NasdaqCM: VRDN traded near $18.79 on Wednesday. Viridian Therapeutics, Inc. has a market capitalization of approximately $2.03 billion. The company is not profitable, which results in no meaningful P/E ratio. The stock has a 52-week low of $13.18 and a high of $34.29. It has a 50-day moving average of $16.21 and a 200-day moving average of $24.11. Viridian boasts a strong liquidity position with a current ratio of 15.15 and a quick ratio of 14.71. The company's debt-to-equity ratio stands at 8.39.
$VRDN price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
In its most recent financial results, Viridian Therapeutics reported revenue of $70.9 million, with a revenue growth rate of 95.8%. The company is not yet profitable, as indicated by a net margin of 0.0% and a return on equity of -58.1%. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at Viridian Therapeutics, Inc.
Insider activity at Viridian Therapeutics has been notable. On May 11, 2026, Fairmount Funds Management LLC acquired 1,176,470 shares at an average price of $17.00. Earlier in the year, on March 3, several executives sold shares at $30.19 each, including Chief Legal Officer Jennifer Tousignant with 1,675 shares, Chief Operating Officer Thomas Beetham with 3,048 shares, CFO Seth Harmon with 2,031 shares, and CEO Stephen Mahoney with 7,408 shares. Jennifer Tousignant also bought 5,169 shares on the same day.
Analysts Set New Price Targets
On June 30, 2026, RBC Capital maintained its buy rating for Viridian Therapeutics with a price target of $35. Truist Securities, Wedbush, and Needham also maintained their buy ratings with targets of $38, $43, and $34, respectively. Wells Fargo upgraded the stock to a buy with a target of $31 on June 29, 2026. The consensus among 16 analysts is a strong buy, with an average price target of $35.5.
About Viridian Therapeutics
Viridian Therapeutics, Inc., headquartered in Waltham, Massachusetts, is a biotechnology company focused on developing treatments for serious and rare diseases. It is working on IGF-1R therapies to treat thyroid eye disease, including Veligrotrug and Elegrobart, as well as an anti-thyroid-stimulating hormone receptor candidate for Graves' disease. The company also develops engineered inhibitors for neonatal Fc receptor, including VRDN-006 and VRDN-008.
Bottom Line
RBC Capital's reiterated buy rating for Viridian Therapeutics with a $35 target reflects continued confidence in the company's prospects. Investors should note that 13F filings and analyst ratings are backward-looking and may not reflect the most current market conditions. Viridian's focus on rare disease treatments and strong institutional interest make it a stock to watch.
Get Viridian Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $VRDN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.